logo
A beautiful bond: Loss, love and blessings on Father's Day

A beautiful bond: Loss, love and blessings on Father's Day

Yahooa day ago

When I was 18-years-old, newly graduated from high school and excited about going to Furman University in Greenville, South Carolina, we got the news. My healthy, fit daddy was diagnosed with stage four lymphoma. The prognosis was not good. Though it has been 52 years since that summer, I still recall vividly how conflicted I was about even leaving home for college, something I had aspired to and my mother insisted upon.
By the grace of God, the stamina of my father, and the remarkably good care he received those long years ago from my mother and his medical team, he ended up living well beyond my college years into his 80s. His beloved oncologist called it a miracle, and so did we.
What I am realizing as this Father's Day approaches is that every child is not so fortunate as was I. There are countless children, my own father included, who lose a father way too early and have to learn to live with a void that is at best painful. That pain is intensified when the loss is traumatic, as is true for the children of the two fathers who were killed in our community during the horrific April 17 shooting at FSU.
Like Mother's Day, Father's Day is not as simple as it seems. On this day set aside to honor and remember our fathers, some of us recall a father who grounded us, gave us a sense of security, and encouraged us to dream dreams and become our best selves.
Others of us remember a father who, for whatever reason, could not or cannot bless us, the absent father, either emotionally or physically, the one we longed or long to impress, but it seems we never could. Still others remember a father who was somewhere in-between. And some of us sadly honor fathers who were cruelly taken from us.
What we have learned about the fathers who were tragically killed at FSU, is that they both were fathers who blessed their children. My friend, Robert Morales, was thrilled from the moment that he learned his wife, Betty, was pregnant. And when the sonogram indicated that they were having a girl, his joy intensified.
The bond between Robert and his lovely daughter, Alicia, could not be stronger or sweeter. Without a hint of jealousy, Betty says that their relationship is special and deep. When his beloved daughter, Alicia was born a uniquely beautiful bond was formed between them.
He was the father that every child deserves: safe and steady, endlessly kind, deeply understanding, unshakably encouraging, and delightfully funny. Alicia was Robert's greatest pride.
I am reminded of author, Sam Keene, telling about his father who took great delight in his children. As he was visiting with his father just before the older man died, he had occasion to look back over their life together and to thank his father for the excellent job he had done.
He told his father, "You have always been there whenever any of us children needed you. And across the years, you have given us the best single gift that any parent could give, you took delight in us. In all sorts of ways you let us know that you were glad we were here, that we had value in your eyes, that our presence was a joy and not a burden to you." And that sense of delight in her was what Alicia felt from her father.
Fathers delighting in their children is a tremendous and lasting gift. Theories abound about the importance of the father's blessing and the life-long yearning for acceptance that some experience in its absence.
It has been a joy to me to see the engagement of the young fathers in our family and in the families of their friends, regarding the care of their children. Far more engaged than many fathers of my own generation, it seems to be more socially expected and endorsed for fathers today to be as attentive as mothers.
An opinion column in the New York Times on April 30, 2025, affirms this engagement of fathers. Titled 'A Great Leap Forward for American Fathers,' the author states that American dads are still spending more time with their children than they were pre-COVID. Citing data from the University of Kansas Care Board, 'fathers of children ages 10 and under were doing about seven minutes more per weekday and 18 minutes more per weekend day, for a total of 1.2 hours more child care a week.'
The National Institute of Health reports that involved fathers have a significant positive impact on children's development, including higher academic achievement, better social skills, fewer behavioral problems, and improved emotional well-being.
In studies measuring father involvement in childcare activities, play and affection, household chores, and early learning activities, the positive impact on children, mothers, as well as fathers, is significant.
Years ago, when my oldest grandchild was only 4, she had her first ballet recital. Her classmates, ranging in age from 3 to 5, were precious in their lime green leotards and feathered tutus. During the grand finale, all the dancers were on the stage for a final bow. Each carried their floral bouquet except for one young child who was fighting back the tears and looking bereft.
I am certain I was not alone in wishing I had a bouquet to give her. In what seemed like an eternity, but was in fact only a few moments, a man hurried down the aisle and made his way to the stage, calling to his daughter. He handed her a bouquet, and she hugged him fiercely. The audience cheered with relief. It was a poignant moment of a father blessing his daughter.
It is my prayer that we all might be sensitive to the many ways that Father's Day is experienced and especially sensitive to those who are missing a father. May we all be willing to be a blessing to the children in our lives and may all fathers feel honored on their special day.
Happy Father's Day!
The Rev. Candace McKibben is an ordained minister and pastor of Tallahassee Fellowship.
This article originally appeared on Tallahassee Democrat: A Father's blessing: Managing loss and love on Father's Day

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Record year for annual Children's Clinic golf outing
Record year for annual Children's Clinic golf outing

Yahoo

time44 minutes ago

  • Yahoo

Record year for annual Children's Clinic golf outing

ANDERSON — In its 40th year, the annual Kids Classic Pro-Am golf outing attracted a record number of golfers and donations. Organizer Nancy Anderson said Thursday at the Anderson Country Club that a record 220 golfers took part in the annual fundraiser for the Peyton Manning Children's-St. John's Children's Clinic. Advertisement She said a record $131,000 was raised, bringing the total raised to $3 million since the outing began in 1984. Only in 2020, during the COVID-19 pandemic, was there not an annual golf outing to raise funds for the clinic. 'All the funds go 100% to the Children's Clinic,' she said. St. Vincent Ascension Hospital Kids Classic Pro-Am Organizers Brian Hammond and Nancy Anderson discuss the significance of the St. Vincent Ascension Hospital Kids Classic Pro-Am, which celebrated its 40th anniversary Thursday. Anderson said it was the best event ever with a change having golfers take to the golf course in the morning and afternoon. Advertisement Among those in attendance was the Indiana Pacers mascot, Boomer, and two Pacemates, who appeared following the Pacers' win Wednesday night over Oklahoma City in Game 3 of the NBA Finals. They were joined by the mascot for the Indiana Fever of the WNBA. Aaron Loy of Portland was playing in the golf outing for the fourth time, and is the manager for the Children's Clinic. 'It was a no-brainer for me to play,' Loy said. He said he plays golf just once a year. 'It's amazing to see all these people come out and the impact it has throughout the year for all the kids,' Loy said. The clinic serves around 2,000 kids on an annual basis. Advertisement 'We provide everything from annual testing, lab tests. Anything they need we will take care of it,' Loy said. Andrew Brinks has played on a Fredricks Construction team for six years and also only plays once a year. 'Raising money for the Children's Clinic is what brings us out,' he said. 'We're really interested in helping the local foundations in the Madison County area. We're really happy to support this and they do good work here.' The first golf outing took place in 1984 and was hosted by community icon Carl Erskine and community leader Wilbur Roby. In 2009, Erskine passed the torch to Jim and the late Marilyn Ault, who co-chaired alongside former Golf Channel host and Anderson native Brian Hammons. Advertisement There were signs at the entrance honoring Erskine, Roby and Marilyn Ault. Over the years, the event has drawn support from sports and community icons including Peyton Manning, Sandi Patty, Archie Manning, Bill Polian, Larry Bird, and Bobby 'Slick' Leonard. This year the organizers brought in several professional golfers to join local teams. Hammond said the professional golfers were competing for a $12,000 prize.

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Associated Press

time2 hours ago

  • Associated Press

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 15, 2025-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the Company is taking to strengthen the safety profile in non-ambulatory patients. These steps follow a second reported case of acute liver failure (ALF) resulting in death. The cases of ALF to date have both occurred in non-ambulatory individuals with Duchenne. Sarepta extends its deepest sympathies to the affected families and care teams. Key Safety Initiatives Evaluating and Enhancing Immunosuppressive Regimen: As part of a comprehensive review of safety data, Sarepta is taking proactive steps to mitigate the risk of acute liver failure in non-ambulatory patients. Sarepta is working to immediately convene an independent group of leading experts in Duchenne and liver health to consider an enhanced immunosuppression regimen for ELEVIDYS. This panel will evaluate data and assess our proposed regimen, which includes sirolimus and is supported by preclinical data demonstrating the effectiveness of additional immunosuppression in moderating liver enzyme elevations, a key factor in mitigating potential safety events. Sarepta will share the panel's recommendations with the U.S. Food & Drug Administration (FDA), and implementation of any new regimen will be subject to FDA guidance and allowance. Suspending Shipments of ELEVIDYS for Non-Ambulatory Patients: Sarepta is temporarily suspending shipments of ELEVIDYS for non-ambulatory patients while an enhanced immunosuppressive regimen is evaluated, discussed with regulatory bodies, and put in place. For ambulatory patients, no treatment changes are being proposed and the current practice of administering corticosteroids before and after ELEVIDYS infusion, along with post-treatment monitoring, remains the same. ENVISION Study Paused: Sarepta has voluntarily paused dosing in the ENVISION clinical study (also known as Study SRP-9001-303). FDA concurs with this action. The pause will allow for the evaluation of a protocol amendment to incorporate an enhanced immunosuppressive regimen for the non-ambulatory patient cohort and incorporate any additional feedback from the FDA. Regulatory alignment is needed before screening and dosing in ENVISION may resume. ENVISION is a global, randomized, double-blind, placebo-controlled trial evaluating ELEVIDYS in older ambulatory and non-ambulatory individuals living with Duchenne muscular dystrophy. In the U.S., it serves as the confirmatory trial required under the FDA's accelerated approval pathway for non-ambulatory patients. 'Our paramount priority is the safety and well-being of the patients we serve. We are taking immediate, decisive steps to better understand and mitigate the risk of acute liver failure, including enhancing the immunosuppressive regimen, for those with Duchenne who are non-ambulatory,' said Louise Rodino-Klapac, Ph.D., chief scientific officer and head of research & development, Sarepta. 'We are deeply saddened by the loss of a second patient and extend our heartfelt condolences to the patient's family and his care team during this incredibly difficult time. Duchenne muscular dystrophy is a devastating disease that profoundly affects lives and often cuts them far too short. With more than 900 individuals treated to-date, we know how much hope families place in new treatment options like ELEVIDYS – and we are committed to honoring that hope by acting swiftly, guided by scientific rigor and the insights of leading experts, to strengthen safety for all future patients.' Commitment to Long-Term Safety and Understanding Sarepta remains committed to a thorough approach and the highest standards of patient safety and scientific rigor. The event has been reported to FDA and global health authorities and will inform ongoing discussions around a potential label update to reflect the risk of severe ALF and additional immune management strategies for non-ambulatory patients. While elevated liver enzymes are a known class effect of all AAV-based gene therapies, the exact mechanism behind AAV-related liver toxicity remains unclear. Current evidence suggests it is likely driven by an adaptive immune response. The Company will provide additional updates as appropriate. Investor Conference Call Details Sarepta will be hosting a conference call and webcast to discuss this update and provide an update on the Company's business on Monday, June 16, 2025, at 8:00 am Eastern time. The event will be webcast live under the investor relations section of Sarepta's website at: and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Acute Serious Liver Injury: Immune-mediated Myositis: Myocarditis: Preexisting Immunity against AAVrh74: Adverse Reactions: Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website We encourage investors and potential investors to consult our website regularly for important information about us. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials, ELEVIDYS, the potential benefits of an enhanced immunosuppression regimen in dosing in non-ambulatory patients, and expected plans and milestones, including providing additional updates as appropriate and engaging with regulators on an enhanced immunosuppressive regimen for dosing in non-ambulatory patients. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; success in clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or with advisory committee recommendations, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; we may not be able to comply with all FDA requests in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to source version on CONTACT: Investor Contact: Ian Estepan 617-274-4052 [email protected] Contacts: Tracy Sorrentino 617-301-8566 [email protected] Hoeger 617-710-3898 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: INFECTIOUS DISEASES HEALTH GENETICS PHARMACEUTICAL CLINICAL TRIALS SOURCE: Sarepta Therapeutics, Inc. Copyright Business Wire 2025. PUB: 06/15/2025 01:00 AM/DISC: 06/15/2025 01:01 AM

NovoSculpt Named Best Body Contouring Clinic in the Tri-State Area for 2025
NovoSculpt Named Best Body Contouring Clinic in the Tri-State Area for 2025

Associated Press

time2 hours ago

  • Associated Press

NovoSculpt Named Best Body Contouring Clinic in the Tri-State Area for 2025

NovoSculpt has been honored as the Best Body Contouring Clinic in the Tri-State Area for 2025, solidifying its place as a leader in aesthetic care and body sculpting services. Greenwich, CT, USA, June 15, 2025 -- NovoSculpt Celebrates Prestigious Recognition in Body Contouring Excellence NovoSculpt proudly announces its recognition as the Best Body Contouring Clinic in the Tri-State Area for 2025, a prestigious title that highlights the clinic's leadership in the rapidly growing field of body sculpting. The award emphasizes NovoSculpt's unwavering commitment to providing safe, effective, and customized solutions for those seeking transformative aesthetic results. The recognition celebrates the clinic's dedication to patient care, innovative treatments, and personalized experiences, solidifying its position as the premier destination for body contouring in the region. NovoSculpt's approach to aesthetic medicine continues to disrupt traditional methods by focusing on minimally invasive treatments that provide lasting and natural results. A Cutting-Edge Approach to Minimally Invasive Fat Removal At the heart of NovoSculpt's success is its groundbreaking minimally invasive fat removal procedure, which allows patients to remove up to 11 pounds of localized fat in a single session. This innovative technique eliminates the need for scalpels, stitches, or general anesthesia, providing a safe and efficient solution for body sculpting. The procedure ensures a quick recovery time, with many patients resuming their daily activities in as little as 24 hours. NovoSculpt's approach has proven to be a highly effective and patient-friendly alternative to traditional body contouring surgeries, enabling clients to achieve their desired body shape with minimal discomfort and downtime. This cutting-edge method continues to set NovoSculpt apart from other clinics in the Tri-State Area and positions the clinic as a trailblazer in the aesthetic industry. Led by Expertise: Roberto Magana and a Skilled Team NovoSculpt's success is driven by the vision and leadership of its founder and CEO, Roberto Magana, MBA. With over 15 years of experience in business strategy and leadership, Roberto's guidance has been pivotal in shaping the clinic's operations and ensuring the highest standards of care. Under his leadership, NovoSculpt has assembled a highly skilled team of medical professionals, including elite plastic surgeons and experienced staff, all of whom are dedicated to delivering exceptional results for every patient. Roberto's commitment to operational excellence and patient satisfaction has been integral to the clinic's rapid growth and its recognition as the top body contouring clinic in the region. The clinic's collaboration with top-tier medical personnel ensures that each patient receives comprehensive care, with personalized treatment plans designed to meet their unique goals. Building Trust with Transparent and Safe Practices NovoSculpt's reputation is built on trust, transparency, and an unwavering focus on safety. The clinic operates within a QuadA-certified surgical suite, ensuring that every procedure is conducted in a safe and controlled environment. This certification is a reflection of the clinic's commitment to adhering to the highest medical and safety standards, providing clients with peace of mind throughout their body sculpting journey. By prioritizing patient safety and comfort, NovoSculpt has earned a loyal clientele who often return to enhance additional areas or recommend the clinic to others—confident in its ability to deliver authentic, natural-looking results in a single session. The clinic's client-first approach has fostered strong, lasting relationships with patients, many of whom experience meaningful boosts in confidence and overall well-being. Patient Satisfaction and Proven Results NovoSculpt's minimally invasive approach consistently results in high patient satisfaction, with many clients experiencing impressive, natural-looking results after just one session. The clinic's innovative fat removal procedure has become the preferred choice for those seeking to reshape their bodies without undergoing more invasive surgical procedures. In addition to fat removal, NovoSculpt offers a range of aesthetic treatments, including skin tightening with NovoTight™ and fat transfer for sculpted curves. These services are customized to each patient's specific needs, ensuring that every treatment plan aligns with their personal aesthetic vision. This personalized approach has contributed to NovoSculpt's reputation for excellence and its status as the top body contouring clinic in the Tri-State Area. A Vision of Innovation and Care NovoSculpt's success story is one of innovation, care, and patient-centric solutions. Founded by Roberto Magana, the clinic was created with the goal of offering a minimally invasive, highly effective approach to body contouring. Roberto's vision has led to the development of a clinic that fills the gaps in the market for minimally invasive, customized body sculpting treatments that deliver lasting results. As the clinic continues to innovate and grow, NovoSculpt's commitment to patient satisfaction and exceptional care remains at the forefront. The clinic's ability to adapt to changing industry trends while maintaining its focus on personalized, safe, and effective treatments has allowed it to remain a leader in the body contouring field. Celebrating Success: The 2025 Recognition NovoSculpt's recognition as the Best Body Contouring Clinic in the Tri-State Area for 2025 is a monumental achievement that celebrates the clinic's leadership, innovation, and dedication to its patients. This award reaffirms NovoSculpt's position as a disruptor in the body contouring industry, offering cutting-edge treatments that prioritize both safety and transformative results. As the clinic looks toward the future, it remains committed to setting the standard for excellence in aesthetic medicine. With a growing reputation for delivering remarkable body sculpting results, NovoSculpt continues to reshape the way individuals approach body contouring and aesthetic care. About NovoSculpt NovoSculpt is a leading body contouring clinic based in Greenwich, Connecticut, specializing in minimally invasive targeted fat removal, precision skin tightening, and aesthetic fat transfers—all performed to enhance body contours with immediate, visible results after a single session. No repeat treatments are necessary. Serving clients across the Tri-State Area and beyond, the clinic offers personalized body sculpting solutions tailored to each patient's goals. Founded by Roberto Magana, MBA, NovoSculpt combines cutting-edge technology, a skilled medical team, and a patient-centered approach to deliver safe, effective, and lasting results—without the need for traditional surgery. Media Contact Roberto Magana, MBA Founder & CEO, NovoSculpt Website: Email: [email protected] Instagram: @novosculptus Facebook: @NovoSculpt TikTok: @novosculptus LinkedIn: NovoSculpt Contact Info: Name: Roberto Magana Email: Send Email Organization: NovoSculpt Website: Release ID: 89162338 If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store